Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1528-1534

  Shin, Hye Sun ^a   Kim, Seung Up ^a,b   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Han, Kwang Hyub ^a,b,c   Chon, Chae Yoon ^a,b   Baatarkhuu, Oidov ^d   Ahn, Sang Hoon ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

^d Health Sciences University   (Mongolia)

Author keywords

Efficacy; Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ENTECAVIR; LAMIVUDINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; HYPOVOLEMIC SHOCK; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME;

EID: 84865377664     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07145.x     Document Type: Article

References (38)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Alves RC, Alves D, Guz B etal. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann. Hepatol. 2011; 10: 21-7.
3. Llovet JM, Real MI, Montana X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
4. Sumie S, Yamashita F, Ando E etal. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am. J. Roentgenol. 2003; 181: 1327-34.
5. Park JY, Ahn SH, Yoon YJ etal. Repetitive short course hepatic arterial infusion chemotherapy with high dose 5 fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-37.
6. Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
7. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
8. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev. Anticancer Ther. 2009; 9: 739-45.
9. Kim SU, Kim DY, Park JY etal. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J. Cancer Res. Clin. Oncol. 2008; 134: 1377-84.
10. McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin. Liver Dis. 2010; 14: 461-76.
11. Kim JH, Park JW, Koh DW, Lee WJ, Kim CM. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2009; 29: 203-7.
12. Koda M, Nagahara T, Matono T etal. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern. Med. 2009; 48: 11-17.
13. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J. Manag. Care Pharm. 2008; 14: 21-33.
14. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 138-43.
15. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-20.
16. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-10.
17. Ueno S, Tanabe G, Nuruki K etal. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol. Res. 2002; 24: 395-403.
18. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
19. Kim DY, Kim SU, Ahn SH etal. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig. Dis. Sci. 2009; 54: 1758-63.
20. Park JW. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma.] Korean J. Hepatol. 2004; 10: 88-98.
21. Chon YE, Kim SU, Lee CK etal. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir. Ther. (Lond.) 2011; 16: 469-77.
22. Lee JM, Ahn SH, Kim HS etal. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-93.
23. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J. Hepatol. 2008; 48 (Suppl. 1): S2-19.
24. Yu MW, Yeh SH, Chen PJ etal. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst. 2005; 97: 265-72.
25. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-84.
26. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011; 31: 111-16.
27. Lai CL, Dienstag J, Schiff E etal. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003; 36: 687-96.
28. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
29. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
30. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-55.
31. Jang JW, Kwon JH, You CR etal. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir. Ther. (Lond.) 2011; 16: 969-77.
32. Watanabe M, Shibuya A, Takada J etal. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur. J. Intern. Med. 2010; 21: 333-7.
33. Jang JW, Choi JY, Bae SH etal. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo lipiodolization. Hepatology 2006; 43: 233-40.
34. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 813-19.
35. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol. Int. 2011. doi 10.1007/s12072-011-9279-6 [Epub ahead of print].
36. Piao CY, Fujioka S, Iwasaki Y etal. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med. Okayama 2005; 59: 217-24.
37. Jin YJ, Shim JH, Lee HC etal. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011; 26: 1380-8.
38. Woo SM, Park JW, Lee WJ, Kim CM. Clinical and virological responses to clevudine therapy of hepatocelluar carcinoma patients with chronic hepatitis B. Gut Liver 2011; 5: 82-7.